Literature DB >> 16969581

Analyses of the associations between the genes of 22q11 deletion syndrome and schizophrenia.

Tadao Arinami1,2.   

Abstract

Schizophrenia is a severe, debilitating mental disorder characterized by profound disturbances of cognition, emotion and social functioning. The lifetime morbid risk is surprisingly uniform at slightly less than 1% across different populations and different cultures. The evidence of genetic risk factors is our strongest clue to the cause of schizophrenia. Linkage and association analyses have identified genes associated with the development of schizophrenia. However, most of the alleles or haplotypes identified thus far have only a weak association or are reported to be population specific. A deletion of 22q11.2 that causes the most common microdeletion syndrome (22q11DS) with an estimated prevalence of 1:2,500-1:4,000 live births may represent one of the greatest known genetic risk factors for schizophrenia. Schizophrenia is a late manifestation in approximately 30% of patients with 22q11.2 deletion, comparable to the risk to offspring of two parents with schizophrenia. Clinical and neuroimaging assessments indicate that 22q11DS-schizophrenia is a neurodevelopmental model of schizophrenia. Recent studies have provided evidence that haploinsufficiency of TBX1 is likely to be responsible for many of the physical features associated with the deletion. Most of the genes in the 22q11 deletion region are conserved together on mouse chromosome 16, enabling the generation of mouse models. Similarities in the cardiovascular and other phenotypes between 22q11DS patients and mouse models can provide important insights into roles of genes in neurobehavioral phenotypes. Because more than one gene in the 22q11DS region is likely to contribute to the marked risk for schizophrenia, further extensive studies are necessary. Analyses of 22q11DS will help clarify the molecular pathogenesis of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16969581     DOI: 10.1007/s10038-006-0058-5

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  87 in total

1.  Neurocognitive profile in 22q11 deletion syndrome and schizophrenia.

Authors:  Eva W C Chow; Mark Watson; Donald A Young; Anne S Bassett
Journal:  Schizophr Res       Date:  2006-06-06       Impact factor: 4.939

2.  Case-control study and transmission disequilibrium test provide consistent evidence for association between schizophrenia and genetic variation in the 22q11 gene ZDHHC8.

Authors:  Wu-Yan Chen; Yong-Yong Shi; Yong-Lan Zheng; Xin-Zhi Zhao; Guang-Ji Zhang; Sheng-Qi Chen; Pei-Di Yang; Lin He
Journal:  Hum Mol Genet       Date:  2004-10-15       Impact factor: 6.150

3.  Implications of normal brain development for the pathogenesis of schizophrenia.

Authors:  D R Weinberger
Journal:  Arch Gen Psychiatry       Date:  1987-07

4.  An investigation of the neuropsychological profile in adults with velo-cardio-facial syndrome (VCFS).

Authors:  J C Henry; T van Amelsvoort; R G Morris; M J Owen; D G M Murphy; K C Murphy
Journal:  Neuropsychologia       Date:  2002       Impact factor: 3.139

5.  Genetic factors are major determinants of phenotypic variability in a mouse model of the DiGeorge/del22q11 syndromes.

Authors:  I Taddei; M Morishima; T Huynh; E A Lindsay
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-18       Impact factor: 11.205

Review 6.  Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies.

Authors:  D L Braff; M A Geyer; N R Swerdlow
Journal:  Psychopharmacology (Berl)       Date:  2001-07       Impact factor: 4.530

7.  Identification of a novel nuclear localization signal in Tbx1 that is deleted in DiGeorge syndrome patients harboring the 1223delC mutation.

Authors:  Jason Z Stoller; Jonathan A Epstein
Journal:  Hum Mol Genet       Date:  2005-02-09       Impact factor: 6.150

8.  Screening for 22q11 deletions in a schizophrenia population.

Authors:  T Arinami; T Ohtsuki; K Takase; H Shimizu; T Yoshikawa; H Horigome; J Nakayama; M Toru
Journal:  Schizophr Res       Date:  2001-12-01       Impact factor: 4.939

9.  VEGF: a modifier of the del22q11 (DiGeorge) syndrome?

Authors:  Ingeborg Stalmans; Diether Lambrechts; Frederik De Smet; Sandra Jansen; Jian Wang; Sunit Maity; Paige Kneer; Maren von der Ohe; Ann Swillen; Christa Maes; Marc Gewillig; Daniel G M Molin; Peter Hellings; Thurid Boetel; Maartin Haardt; Veerle Compernolle; Mieke Dewerchin; Stephane Plaisance; Robert Vlietinck; Beverly Emanuel; Adriana C Gittenberger-de Groot; Peter Scambler; Bernice Morrow; Deborah A Driscol; Lieve Moons; Camila V Esguerra; Geert Carmeliet; Annett Behn-Krappa; Koen Devriendt; Désiré Collen; Simon J Conway; Peter Carmeliet
Journal:  Nat Med       Date:  2003-01-21       Impact factor: 53.440

10.  A haplotype implicated in schizophrenia susceptibility is associated with reduced COMT expression in human brain.

Authors:  Nicholas J Bray; Paul R Buckland; Nigel M Williams; Hywel J Williams; Nadine Norton; Michael J Owen; Michael C O'Donovan
Journal:  Am J Hum Genet       Date:  2003-06-11       Impact factor: 11.025

View more
  21 in total

Review 1.  The 22q11.2 deletion syndrome as a window into complex neuropsychiatric disorders over the lifespan.

Authors:  Rachel K Jonas; Caroline A Montojo; Carrie E Bearden
Journal:  Biol Psychiatry       Date:  2013-08-28       Impact factor: 13.382

Review 2.  Bridging the gene-behavior divide through neuroimaging deletion syndromes: Velocardiofacial (22q11.2 Deletion) and Williams (7q11.23 Deletion) syndromes.

Authors:  Daniel Paul Eisenberg; Mbemba Jabbi; Karen Faith Berman
Journal:  Neuroimage       Date:  2010-03-03       Impact factor: 6.556

Review 3.  22q11.2 microdeletions: linking DNA structural variation to brain dysfunction and schizophrenia.

Authors:  Maria Karayiorgou; Tony J Simon; Joseph A Gogos
Journal:  Nat Rev Neurosci       Date:  2010-06       Impact factor: 34.870

4.  Genetic and functional studies of phosphatidyl-inositol 4-kinase type IIIα.

Authors:  Zsofia Szentpetery; Gergely Szakacs; Naveen Bojjireddy; Andrew W Tai; Tamas Balla
Journal:  Biochim Biophys Acta       Date:  2011-05-13

Review 5.  Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia.

Authors:  Hayley B Clay; Stephanie Sillivan; Christine Konradi
Journal:  Int J Dev Neurosci       Date:  2010-09-15       Impact factor: 2.457

6.  Ultra high risk status and transition to psychosis in 22q11.2 deletion syndrome.

Authors:  Maude Schneider; Marco Armando; Maria Pontillo; Stefano Vicari; Martin Debbané; Frauke Schultze-Lutter; Stephan Eliez
Journal:  World Psychiatry       Date:  2016-10       Impact factor: 49.548

Review 7.  Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects.

Authors:  Maarten van den Buuse
Journal:  Schizophr Bull       Date:  2009-11-09       Impact factor: 9.306

8.  Microarray comparative genomic hybridization analysis of 59 patients with schizophrenia.

Authors:  Takeshi Mizuguchi; Ryota Hashimoto; Masanari Itokawa; Akira Sano; Osamu Shimokawa; Yukiko Yoshimura; Naoki Harada; Noriko Miyake; Akira Nishimura; Hirotomo Saitsu; Nadiya Sosonkina; Norio Niikawa; Hiroshi Kunugi; Naomichi Matsumoto
Journal:  J Hum Genet       Date:  2008-08-07       Impact factor: 3.172

Review 9.  Schizophrenia and 22q11.2 deletion syndrome.

Authors:  Anne S Bassett; Eva W C Chow
Journal:  Curr Psychiatry Rep       Date:  2008-04       Impact factor: 5.285

Review 10.  Phosphoinositides: tiny lipids with giant impact on cell regulation.

Authors:  Tamas Balla
Journal:  Physiol Rev       Date:  2013-07       Impact factor: 37.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.